So curiosity got the better of me and I took Akki off ignore momentarily...
Summary:
- Me: if we're successful with the PIIb DMD trial, are we a chance for off-label use?
- Akki: other indications haven't succeeded, why will this one be different?
The deliberate misdirection away from a genuine question tells me all I need to know re motive; back on ignore.
If any knowledgeable posters have some insight into the original question, I'm still curious.
Cheers.
Ann: New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2, page-32
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $58.09K | 574.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38503 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 194063 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |